



12 August 2016

To: Recipients of M45, 3rd ed.

From: Jennifer K. Adams, MT(ASCP), MSHA

Subject: Editorial Footnote Errors in Tables 22 and 24A, and updates to Overview of Changes in CLSI Document M45

This notification is to inform you of footnote errors and an update to the Overview of Changes in CLSI document M45, 3rd ed., *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria*.

The details of each change are below.

There are two footnote errors in Table 22.

In Table 22, the MIC Test Medium column (column 3) for *Vibrio* spp. originally cited footnote “d,” which referred to quality control (QC) for carbapenams. The footnote that should have been cited refers to inoculum preparation. Due to footnote reordering while resolving this error, the footnote is still “d” but the footnote text now refers to inoculum preparation.

In the QC Strains column (column 6), the *B. pseudomallei* row originally cited footnote “c” for *E. coli* ATCC® 35218, which referred to inoculum preparation. The text has been corrected to cite footnote “b,” which refers to using *E. coli* ATCC® 35218 for QC when testing β -lactam/ β -lactamase inhibitor combination drugs.

The footnote citations have been corrected and the footnotes have been reordered per CLSI style. The affected rows are shown in the Table 22 excerpt below, with the changed footnotes highlighted:



Table 22. Summary of Testing Conditions and Quality Control Recommendations for Infrequently Isolated or Fastidious Bacteria

Table No.	Organism/Organism Group	Broth Microdilution MIC Test Method	Broth Microdilution MIC Incubation Conditions	Disk Diffusion Test Medium/Incubation Conditions	QC Strain(s) (see Tables for QC Ranges)
20	<i>Vibrio</i> spp. (including <i>V. cholerae</i>)	CAMHB ^a	35°C; ambient air; 16–20 h	MHA (unsupplemented/35°C; ambient air; 16–18 h) ^d	<i>E. coli</i> ATCC® 25922 <i>E. coli</i> ATCC® 35218 ^b <i>P. aeruginosa</i> ATCC® 27583^c
Potential Bacterial Agents of Bioterrorism					
21	<i>B. pseudomallei</i>	CAMHB	35°C; ambient air; 16–20 h	N/A	<i>E. coli</i> ATCC® 25922 <i>E. coli</i> ATCC® 35218^b <i>P. aeruginosa</i> ATCC® 27853

Abbreviations: ATCC®, American Type Culture Collection; CAMHB, cation-adjusted Mueller-Hinton broth; CAMHB-LHB, cation-adjusted Mueller-Hinton broth supplemented with lysed horse blood; QC, quality control; MHA, Mueller-Hinton agar; MIC, minimal inhibitory concentration; N/A, not applicable; No., number.

Footnotes

- ATCC® is a registered trademark of the American Type Culture Collection.
- E. coli* ATCC® 35218 is used for QC when testing β -lactam/ β -lactamase inhibitor combination drugs.
- P. aeruginosa* ATCC® 27583 is used for QC when testing carbapenems.**
- Prepare inoculum in 0.85% NaCl (normal saline).

NOTE: Information in boldface type is new or modified since the previous edition.

There is a reference error in footnote “b” in Table 24A.

In Table 24A, footnote “b” currently cites CLSI document M07 as a reference; however, CLSI document M02 is the correct reference. Footnote “b” has been corrected to read “refer to CLSI document M02” and the reference citation has been corrected. This change is highlighted below.



Table 24A. Disk Diffusion: Quality Control Ranges for Nonfastidious Organisms (Unsupplemented Mueller-Hinton Medium)

Antimicrobial Agent	Disk Content	Disk Diffusion QC Ranges (mm)			
		<i>E. coli</i> ATCC® ^a 25922	<i>S. aureus</i> ATCC® 25923	<i>E. coli</i> ATCC® 35218 ^b	<i>P. aeruginosa</i> ATCC® 27853
Amikacin	30 µg	19–26	20–26	–	–
Amoxicillin-clavulanate	20/10 µg	18–24	28–36	17–22	–
Ampicillin	10 µg	16–22	27–35	6	–
Ampicillin-sulbactam	10/10 µg	19–24	29–37	13–19	–
Azithromycin	15 µg	–	21–26	–	–
Aztreonam	30 µg	28–36	–	–	–
Cefazolin	30 µg	21–27	29–35	–	–
Cefepime	30 µg	31–37	23–29	–	–
Cefotaxime	30 µg	29–35	25–31	–	–
Cefoxitin	30 µg	23–29	23–29	–	–
Ceftazidime	30 µg	25–32	16–20	–	–
Ceftriaxone	30 µg	29–35	22–28	–	–
Cefuroxime	30 µg	20–26	27–35	–	–
Cephalothin	30 µg	15–21	29–37	–	–
Chloramphenicol	30 µg	21–27	19–26	–	–
Ciprofloxacin	5 µg	30–40	22–30	–	–
Clarithromycin	15 µg	–	26–32	–	–
Doripenem	10 µg	–	–	–	28–35
Doxycycline	30 µg	18–24	23–29	–	–
Ertapenem	10 µg	29–36	24–31	–	13–21
Erythromycin	15 µg	–	22–30	–	–
Gentamicin	10 µg	19–26	19–27	–	–
Imipenem	10 µg	26–32	–	–	20–28
Levofloxacin	5 µg	29–37	25–30	–	–
Meropenem	10 µg	28–34	29–37	–	27–33
Ofloxacin	5 µg	29–33	24–28	–	–
Piperacillin	100 µg	24–30	–	12–18	–
Piperacillin-tazobactam	100/10 µg	24–30	27–36	24–30	–
Tetracycline	30 µg	18–25	24–30	–	–
Trimethoprim-sulfamethoxazole	1.25/23.75 µg	23–29	24–32	–	–

Abbreviations: ATCC®, American Type Culture Collection; QC, quality control.

Footnotes

- a. ATCC® is a registered trademark of the American Type Culture Collection.
- b. Because *E. coli* ATCC® 35218 may lose its plasmid, careful organism maintenance is required; refer to CLSI document **M07M02.12**

NOTE: Information in boldface type is new or modified since the previous edition.

Setting the **Global**
Standard for Quality
in Laboratory Testing



P: +1.610.688.0100
Toll Free (US): 877.447.1888
F: +1.610.688.0700
E: customerservice@clsi.org

950 West Valley Road
Suite 2500
Wayne, PA 19087 USA



**CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®**

As a result of a comment submitted during the Proposed Draft vote, the breakpoints for cepheims were deleted from Table 4, *Bacillus* spp. (Not *Bacillus anthracis*) and Related Genera. However, this deletion was not noted in the Overview of Changes in the published document. Therefore, the following text has been added for Table 4 in the Overview of Changes: “Deleted the cephalosporin breakpoints due to ability of *Bacillus* spp. to produce potent cephalosporinases.”

If you require any additional clarification regarding this correction, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI, and regret any inconvenience.